.RESEARCH STUDY EMPHASIZE.06 August 2024.
A huge randomized measured trial with cisgender women highlights the challenges of obedience to a regular oral preexposure treatment routine and also displays that twice-yearly injection of lenacapavir can easily preserve helpful HIV deterrence levels over 6 months.